XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Cross Below 50 Day Moving Average – Should You Sell?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s stock price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.56 and traded as low as $2.07. XTL Biopharmaceuticals shares last traded at $2.23, with a volume of 26,382 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Up 8.3%

The company has a fifty day simple moving average of $2.56 and a 200-day simple moving average of $4.72. The firm has a market cap of $4.91 million, a P/E ratio of -3.48 and a beta of 1.48.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.